Thoracic medical oncologist @MDAndersonNews, former hospitalist/clinical informaticist @UCLA, love classical music and nature.
- Tweets 288
- Following 402
- Followers 735
- Likes 1,638
Bingnan Zhang retweeted
Agree, lung cancer ADC/BsAb pipelines look the same.
We mapped 47 active trials (@ClinLungCancer):
• BsAbs ~70% / ADCs ~30%
• Top BsAb: EGFR×c-MET (~28%)
• Top ADC: TROP2 (~33%), HER2 (~20%)
Same few antigens. More me-too than novel.
doi.org/10.1016/j.cllc.2024.…
Since people are talking about target crowding, here's a chart from an upcoming post: <5% of new drugs entering the clinic are going after targets that haven't been tested clinically before, ~60% are going after targets with an approved drug. New ideas are hard to find!
1
15
52
4,141
Bingnan Zhang retweeted
🔥 Outstanding piece of work published today in Nature Medicine!
Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏
The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy?
This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients.
Congratulations to everyone involved! 👏
🔗 nature.com/articles/s41591-0…
Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors
#ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch
2
32
88
11,317
Bingnan Zhang retweeted
Important longer follow up from DeLLphi-304 (2L tarlatamab vs SCLC) presented by Dr. @charlesrudin at #ESMO26 simultaneously published @Annals_Oncology. Median PFS 4.2 vs 3.2m, mOS 13.6 vs 8.4m, 2y OS 30% vs 15%, RR 35% vs 20% #ESMOAmbassadors
annalsofoncology.org/article…
2
14
42
2,727
Bingnan Zhang retweeted
Now in Nature w simultaneous presentation #ESMO26 #NeoCOAST2 ! 1st platform neoadjuvant trial to associate tumor agnostic ctDNA dynamics w pCR & EFS! Privileged to be part of this effort led by Drs. Lara McGrath & Tina Cascone! Paper/slides below! 1/ #lcsm
nature.com/articles/s41586-0…
3
34
87
6,162
Bingnan Zhang retweeted
#ESMO26 Presidential 1:
As Tarlatamab moves from the 2L to the 1L setting, it suddenly becomes taller 😄😄
Congrats @sands_jacob , we are here to celebrate with you for the dawn of a new era for our patients with #SCLC
@myESMO @SclcSMASHERS @StephenVLiu
4
21
103
5,358
Huge milestone for improving the treatment of extensive stage SCLC. Feeling happy and hopeful for our patients. Huge congratulations to the entire clinical trial team, to Amgen, to the study investigators and the excellent presentation and discussion by @sands_jacob @StevenLin_MDPhD The work continues - let’s make sure tarlatamab gets wide access, and other DLL3 T cell engagers get incorporated into the treatment paradigm (in clinical trials), and let’s find better solutions for those DLL3 T cell engagers don’t work in.
Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated that we might finally be bending gravity. Today, that vision is becoming a reality!!!!!!👏👏👏👏👏
3
13
629
Bingnan Zhang retweeted
Game changing data. Congratulations to the team and gratitude to the patient participants and their families. #SCLC @LUNGevity
#ESMO26 Presidential 1 :
#SCLC DeLLphi-305:
Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC!
#Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42.
80% of patients alive and 38% progression-free at 12 months
The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨
@myESMO @SclcSMASHERS
#ESMOAmbassadors
4
27
979
Bingnan Zhang retweeted
#ESMO26 Presidential 1 :
#SCLC DeLLphi-305:
Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC!
#Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42.
80% of patients alive and 38% progression-free at 12 months
The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨
@myESMO @SclcSMASHERS
#ESMOAmbassadors
1
45
108
5,975
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW
@myESMO
ALT A graph from the Original Article "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." The trial name, DeLLphi-305, is in parentheses after the title. The graph shows the overall survival (intention-to-treat population). The trial results are being presented at the European Society For Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
9
149
506
75,104
Bingnan Zhang retweeted
🚨🔥@OncoAlert Hot off the press.
Just published @NEJM in conjunction with presentation @myESMO #ESMO26
the long-awaited #PracticeChanging results of:
⭐️#DeLLphi305 phase 3 trial of:
❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab.
Study showed:
‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit.
✅#mOS: 21.1 vs 12.7 months (HR 0.42)
✅12-month OS: 79.4% vs 53.3%
✅#mPFS: 7.4 vs 1.9 months (HR 0.34)
⚠️ Grade ≥3 #AEs: 46.8% vs 40.6%
* In Tarlatamab arm:
#CRS: 49.6% (Grade ≥3: 0.4%)
#ICANS: 1.1% (Grade ≥3: 0%)
👇🏻
nejm.org/doi/full/10.1056/NE…
3
44
84
6,656
Bingnan Zhang retweeted
🆙#ESMO26 Proffered Paper I: #LCSM Mets
🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial
🎙️ @decroisette
🔢2614O
🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone
🎯PFS HR 0.56, mPFS 16.1 vs 6.9m
🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo
🎯Grade≥3 TRAEs 53.8% vs 19.3%
☑️NCT04547504
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙 #ESMO26 Proffered Paper I: #LCSM Mets
🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial
🎙️ @decroisette
🔢2614O
☑️NCT04547504
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
20
35
4,784
Scientists have mapped one of the most mysterious parts of the human brain in unprecedented detail
go.nature.com/4zIRwSb
10
156
622
52,211
Bingnan Zhang retweeted
Targeting KRAS-Mutant Lung Cancers
Great review👇
jnccn.org/view/journals/jncc…
1
21
80
3,988
Bingnan Zhang retweeted
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
15
37
2,396
The modern day “ fortune teller” ?:) jokes aside I think these AI models do have lots of potential.
There's a lot in a face photograph about health that AI can detect, as seen in this foundation model of >40 million face images, including outcomes from cancer, biological age, influence of lifestyle factors, and survival @LancetDigitalH
thelancet.com/journals/landi…
115
Bingnan Zhang retweeted
We now have prospective data with TOPO1 ADC sequencing from:
- SATEEN (#ESMOBreast26)
- HER3-DXd (#ESMOBreast26)
- SWITCH (upcoming #ESMO26)
All validate prior retrospective data, showing that TOPO1 ADC resistance is not overcome by target switch.
New payloads urgently needed.
#ESMO26 | SWITCH – Phase II
In mBC progressing after ADC therapy, switching the target antigen while continuing with the same TOP1 inhibitor payload class resulted in ORRs of only 0–8.3%.
Although the sample size was small and the patient population heterogeneous, changing the target antigen alone does not appear sufficient to overcome resistance.
2
42
92
11,925
Bingnan Zhang retweeted
📖 🔥 New online #firmonertinib in EGFR #PACC-mut NSCLC. @Cancer_Cell
👉 Firmonertinib has a trifluoroethoxy group, which enhances its potency against EGFR PACC mutation
👉 68% response rate with firmonertinib 240 mg daily.
Median progression-free survival of 16.0 months at 240 mg.
👉 47% intracranial response rate among patients with baseline brain metastases.
@EGFRResisters @Exon20Group @lungoncdoc @riess_md
Results from the Phase 1b FURTHER trial found a targeted therapy that achieved achieved durable antitumor activity for patients with EGFR PACC-mutated non-small cell lung cancer. @LeXiuning #EndCancer spr.ly/6014BHMzuy
11
40
3,118
Bingnan Zhang retweeted
🚨 Hot off the press! A week before @myESMO annual meeting for everyone to read 👉
🔥Pleased to share with the 🌎our comprehensive review in @CellPressNews @MedCellPress journal Med:
👉“Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology”
👉Precision oncology has transformed cancer therapy, but tumors adapt.
👉One of the most striking escape routes is histological transformation: a cancer that responds beautifully to targeted therapy can change its very identity, from adenocarcinoma to small cell or squamous for example.
👉In this review we examine:
🔹 How different forms of tumor plasticity drive histological transformation as a resistance mechanism across anticancer therapies
🔹 The underlying biology + mechanisms behind these lineage switches
🔹 How precision oncology, informed by a deeper understanding of plasticity, can be used to anticipate, detect + overcome transformation + improve outcomes for patients
👉If we want the next generation of cancer therapies to last, we have to treat cancer as an evolving system, not a static target.
Grateful to an army of amazing co-authors, led by Nick A. Kuburich & @mgoudaMD , with Breanna R. Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, @WIN_Consortium leadership @Dr_R_Kurzrock , @weldeiry , and the one & only guru of EMT @SenduraiMani
#PrecisionOncology #CancerResearch #DrugResistance #TumorPlasticity #EMT #OncTwitter
🧵 A thread soon with the behind-the-scenes story of how this paper came together. Stay tuned! @OncoAlert @oncodaily
🔗 cell.com/med/abstract/S2666-…
2
25
77
8,950
Excited to share new work from our lab: “Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.”
jci.org/articles/view/199454
3
3
25
1,357